Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 7/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18357675 | 0.81 | LIPE (0.42) | LIPEPTGS2CHRM4 | |
| SCHEMBL21410680 | 0.77 | BPTF (0.42) | NR1H2NR1H3L3MBTL1 | |
| SCHEMBL22480002 | 0.77 | KCNA5 (0.44) | PPARDLIPEEPHX2CACNA1BCHRM4 | |
| SCHEMBL15022978 | 0.75 | ACACB (0.52) | — | |
| SCHEMBL1471204 | 0.74 | PPARD (0.42) | PPARDLIPEPOLBL3MBTL1EPHX2 | |
| SCHEMBL1471203 | 0.74 | PPARD (0.42) | PPARDLIPEPOLBL3MBTL1EPHX2 | |
| SCHEMBL1589266 | 0.73 | LIPE (0.59) | LIPE | |
| SCHEMBL11604 | 0.73 | LIPE (0.59) | LIPE | |
| SCHEMBL1471142 | 0.73 | POLB (0.42) | PPARDLIPEPOLBL3MBTL1EPHX2 | |
| SCHEMBL1471144 | 0.73 | POLB (0.42) | PPARDLIPEPOLBL3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308169-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308169-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS | SQOR, NQO1, NDUFS3 | PPARD 128/4885KIF11 4667/4885LIPE 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.